Meeting
2020 ASCO Virtual Scientific Program
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
Presenter
Laura Quan Man Chow, MD
University of Washington
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03013218
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3056)
DOI
10.1200/JCO.2020.38.15_suppl.3056
Abstract #
3056
Poster Bd #
120
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.
Speaker: Johan Erik Wallin, PhD, MSc, MPharm
Videos & Slides
2023 ASCO Annual Meeting
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
Speaker: Minal A. Barve, MD
Videos & Slides
2023 ASCO Annual Meeting
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
Speaker: Adil Daud, MD
Videos & Slides
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
Speaker: Soohyeon Lee, MD, PhD